Pembrolizumab for Early Triple-Negative Breast Cancer
2020 · New England Journal of Medicine · 2,944 citations
https://doi.org/10.1056/nejmoa1910549
L
Lajos Pusztai
Emory University(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.4K
Papers
68.3K
Citations
114
h-index
440
i10-index
Lajos Pusztai is an academic researcher from Emory University. The author has contributed to research in topics: Breast Cancer Treatment Studies & HER2/EGFR in Cancer Research & Cancer Genomics and Diagnostics. The author has an h-index of 114, co-authored 1185 publications.
ORCID: 0000-0001-9632-6686Papers by this author
worksResponse to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
2008 · Journal of Clinical Oncology · 2,876 citations
https://doi.org/10.1200/jco.2007.14.4147
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
2005 · Clinical Cancer Research · 1,869 citations
https://doi.org/10.1158/1078-0432.ccr-04-2421
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
2012 · The Lancet · 1,303 citations
https://doi.org/10.1016/s0140-6736(11)61847-3
Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer
2005 · Journal of Clinical Oncology · 1,165 citations
https://doi.org/10.1200/jco.2005.07.032
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
2009 · The Oncologist · 1,147 citations
https://doi.org/10.1634/theoncologist.2008-0230
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat